Skip to content

Study · Not a test of the peptide alone · 2022

3 results

Weight loss and β-cell responses following gastric banding or pharmacotherapy in adults with impaired glucose tolerance or type 2 diabetes: a randomized trial.

Utzschneider KM, Ehrmann DA, Arslanian SA, Barengolts E, Buchanan TA, Caprio S, Edelstein SL, Hannon TS, Kahn SE, Kozedub A, Mather KJ, Nadeau KJ and 4 more

Show all authors

Sam S, Tripputi M, Xiang AH, El Ghormli L

Obesity (Silver Spring, Md.)1 Aug 2022

PMID35894078 (opens in a new tab)PMCIDPMC10849844 (opens in a new tab)DOI10.1002/oby.23475 (opens in a new tab)PepBankPUB-35894078
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with impaired glucose tolerance or type 2 diabetes, BMI decreased at 12 months in all treatment arms except placebo, including the liraglutide plus metformin arm.

    In plain wordsIn adults with impaired glucose tolerance or type 2 diabetes, BMI fell in every treatment group except placebo, including the liraglutide plus metformin group.

    Peptide
    Liraglutide
    Outcome
    DecreaseBMI change at 12 months
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    BMI decreased in all treatment groups, except placebo, at 12 months.
    2 context sentences
    Summary · context
    The Restoring Insulin Secretion (RISE) Study included adults in the Beta-Cell Restoration Through Fat Mitigation Study (n = 88 randomized to laparoscopic gastric banding or metformin [MET]) and the Adult Medication Study (n = 267 randomized to placebo, MET, insulin glargine/MET, or liraglutide + MET [L + M]).
    Summary · context
    IS and β-cell responses were measured at baseline and after 12 months by modeling of oral glucose tolerance tests and during arginine-stimulated hyperglycemic clamps.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with impaired glucose tolerance or type 2 diabetes, insulin sensitivity increased in all arms except placebo, including the liraglutide plus metformin arm, and was inversely correlated with BMI change.

    In plain wordsIn adults with impaired glucose tolerance or type 2 diabetes, insulin sensitivity rose in every treatment group except placebo, including liraglutide plus metformin.

    Peptide
    Liraglutide
    Outcome
    IncreaseInsulin sensitivity change at 12 months
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    IS increased in all arms except placebo and was inversely correlated with changes in BMI.
    2 context sentences
    Summary · context
    The Restoring Insulin Secretion (RISE) Study included adults in the Beta-Cell Restoration Through Fat Mitigation Study (n = 88 randomized to laparoscopic gastric banding or metformin [MET]) and the Adult Medication Study (n = 267 randomized to placebo, MET, insulin glargine/MET, or liraglutide + MET [L + M]).
    Summary · context
    IS and β-cell responses were measured at baseline and after 12 months by modeling of oral glucose tolerance tests and during arginine-stimulated hyperglycemic clamps.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome

    In adults with impaired glucose tolerance or type 2 diabetes, liraglutide plus metformin was the only treatment arm that enhanced multiple measures of beta-cell function independent of weight loss.

    In plain wordsIn adults with impaired glucose tolerance or type 2 diabetes, only the liraglutide plus metformin group improved several beta-cell measures regardless of weight loss.

    Peptide
    Liraglutide
    Outcome
    IncreaseBeta-cell function independent of weight loss
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Endocrine and hormones

    Source sentences

    Summary
    L + M was the only treatment arm that enhanced multiple measures of β-cell function independent of weight loss.
    2 context sentences
    Summary · context
    The Restoring Insulin Secretion (RISE) Study included adults in the Beta-Cell Restoration Through Fat Mitigation Study (n = 88 randomized to laparoscopic gastric banding or metformin [MET]) and the Adult Medication Study (n = 267 randomized to placebo, MET, insulin glargine/MET, or liraglutide + MET [L + M]).
    Summary · context
    IS and β-cell responses were measured at baseline and after 12 months by modeling of oral glucose tolerance tests and during arginine-stimulated hyperglycemic clamps.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · 1 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3Results postedNCT01779362

RISE Adult Medication Study

RISE Study Groupn = 267Apr 2013 to Aug 2019

Prediabetes · Type 2 Diabetes

Trial pageClinicalTrials.govUpdated 11 May 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.